Press Releases [2004]
ARIADNE GENOMICS AND GENEGO COLLABORATE IN DELIVERING ADVANCED SYSTEMS BIOLOGY TOOLS Rockville, MD and St. Joseph, MI. September 20, 2004 - Ariadne Genomics Inc. and GeneGo, Inc., two leading systems biology companies, today announced integration and co-marketing of tools for functional analysis of high-throughput experimental data. Ariadne Genomics" MedScan TextMiner automated text processing pipeline will be integrated and co-marketed with MetaCore™, GeneGo"s flagship analytical platform that includes proprietary, manually curated databases of human biology and chemistry. "We are pleased to join forces with Ariadne Genomics, the market leader in automated text mining of biomedical information", said Dr. Tatiana Nikolskaya, President and CSO of GeneGo. "MetaCore™ is known for its extensive, expert curated content and analytical tools. Now, we are adding to the platform the most advanced Natural Language Processing (NLP) engine available today. With the integration of MedScan TextMiner, our customers will have more options and flexibility in extracting relevant information from experimental data". "We are happy to collaborate with GeneGo", said Dr. Ilya Mazo, President of Ariadne Genomics. "Our goal is to deliver comprehensive tools for genomic data analysis to the working desk of every scientist, and this collaboration provides researchers with unprecedented power and flexibility in text and data mining. Specifically, they can build and analyze protein-protein, protein-ligand and genetic interaction networks using GeneGo"s high quality databases of human biology and active chemistry. At the same time, they will be able to see the bigger picture with the vast space of protein interactions and regulations extracted from MEDLINE publications, proprietary and public domain databases". MetaCore™ features maps, pathways and networks for almost all known human proteins; parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; seven proprietary network building algorithms; flexible visualization and data exchange tools. MedScan TextMiner utilizes a proprietary Natural Language Processing engine to automatically process MEDLINE abstracts, articles, and other scientific text in TXT, PDF, HTML and other formats. It extracts functional associations among proteins, cell processes, small molecules etc., and recognizes types of regulatory mechanisms involved, and the effects of regulation. About Ariadne Genomics Ariadne Genomics develops software tools for systems biology, based on its innovative Natural Language Processing (NLP) and statistical algorithms: PathwayAssist, an intuitive desktop software tool for reconstruction, analysis and visualization of cell regulatory pathways; MedScan TextMiner, an automated scientific text processing tool, extracting information from MEDLINE abstracts, articles and other text resources; ResNet, a comprehensive molecular networks database, created by automated extraction of biological facts from the entire PubMed, and Seqware, a PC-based BLAST server, storing and managing the entire
GENEGO ADDS BRISTOL-MYERS SQUIBB TO CUSTOMER BASE Company licenses MetaCore™ systems biology database St. Joseph, Michigan, August 10, 2004 - GeneGo, Inc., a leading systems biology company, today announced that Bristol-Myers Squibb has licensed its MetaCore™ data mining suite that combines analytical tools, data content and algorithms for understanding complex interconnected pathways that are affected in common human diseases. MetaCore™'s manually curated content covers all levels of cellular functionality from GPCRs and other receptors to signal transduction cascades, transcriptional factors, core effector networks, endogenous and xenobiotics metabolism and the relevant chemical compounds (metabolites and xenobiotics). The main application of MetaCore™ is in visualization and analysis of complex experimental data including microarray gene expression, SAGE and SNP DNA sequences, proteomics and metabolites profiles. "BMS is the fifth major life science company which licensed MetaCore™ for internal development in recent months" said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "We are pleased that MetaCore™'s features, in particular its curated content and ability to integrate customer-generated data into the database, meet Bristol-Myers Squibb's expectations in systems biology."
GENEGO RELEASES VERSION 2.0 OF METACORE™ Improvements to data parsing systems and user interface increase usability St. Joseph, Michigan, August 9, 2004 - GeneGo, Inc., a leading systems biology company, today released its integrated data mining suite MetaCore™ version 2.0 to the general public. The new version of MetaCore™ features over 300 functional maps of human biology, additional parsers for importing data directly from Affymetrix and Agilent microarrays, analyzed data from Silicon Genetic's GeneSpring and Rosetta's Resolver, SAGE, proteomics and metabolomics data. MetaCore™ also has seven new network building algorithms, and additional visualization tools which enhance the flexibility and efficiency of analysis. MetaCore™ is based on a comprehensive, interactive database of human biology. MetaCore™'s manually curated content covers all levels of cellular functionality from GPCRs and other receptors to signal transduction cascades, transcriptional factors, core effector networks, endogenous and xenobiotics metabolism and the relevant chemical compounds (metabolites, drugs and ligands). The main application of MetaCore™ is in visualization and analysis of complex experimental data including microarray gene expression, SAGE and SNP DNA sequences, proteomics and metabolites profiles. "One of MetaCore™'s key advantages is its integration of many different data types, which enables a multileveled approach to understanding cellular functionality. The completeness of MetaCore™'s content, high confidence in our pathways and interactions and easy-to-use intuitive interface make MetaCore™ 2.0 a valuable resource for life scientists involved in "high-throughput" experimental research," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "Systems biology is a very new area with few guidelines. We listen to our academic and industrial customers and collaborators and develop MetaCore™ to address their needs and wishes. Our proprietary architecture allows us to make changes and enhancements very quickly."
GENEGO ENTERS LICENSING AGREEMENT WITH INVITROGEN CORPORATION St. Joseph, Michigan, June 1, 2004 - GeneGo, Inc., a company with a proprietary computational platform for Systems Biology that combines analytical tools, data content and algorithms for understanding complex interconnected pathways that are affected in common human diseases, today announced that it has entered into a multi-year licensing agreement with Invitrogen Corp. (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery. Under the agreement, the companies plan to work closely together to develop new capabilities. Further details and financial arrangements were not disclosed at this time, but will be divulged in greater detail as milestones of the collaboration are achieved. "We are delighted to work with Invitrogen towards our shared goal of providing life science researchers with the tools they need to produce meaningful answers from their experiments," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "We are impressed with the quality and usability of biological pathways from GeneGo. Licensing of these pathways will help us in making bioinformatics an intrinsic part of Invitrogen's solutions set for life science research," said Michael Stapleton, Ph.D., General Manager and Vice President of Invitrogen's bioinformatics business.
SEAN EKINS, PH.D. JOINS GENEGO AS VICE PRESIDENT OF COMPUTATIONAL BIOLOGY St. Joseph, Michigan, February 23, 2004 - GeneGo today announced that Sean Ekins, Ph.D. joined the Company as the Vice President for Computational Biology. Dr. Ekins is a world renowned scientist in the area of in vitro and computational ADME and toxicity, an important area of pharmaceutical drug discovery and development. Prior to GeneGo, Dr. Ekins held various research positions at Eli Lilly, Pfizer and was most recently Associate Director, Computational Drug Discovery at Concurrent Pharmaceuticals. He has authored over 50 peer reviewed articles, book chapters, reviews as well as several patents relating to computational and screening technologies. Dr. Ekins is also on the editorial boards of several journals. Dr. Ekins earned his Ph.D. from The University of Aberdeen. "We are happy to welcome Dr. Ekins to our team. In addition to his outstanding research record, he brings invaluable hands-on expertise at leading drug companies" said Dr. Tatiana Nikolskaya, President & CSO of GeneGo. "Sean will lead our program in ADME/Tox, namely development of MetaDrug™, a systems biology platform for early prediction of metabolic fate and human toxicity of novel drug molecules". "I am very excited to join GeneGo" said Dr.Ekins, "I was attracted by GeneGo's unique approach to Systems Recontruction technology which links human metabolism with regulation and chemistry. We will leverage this valuable technology in a very novel product in the ADME/Tox area. MetaDrug™ will be capable of analysis of multiple types of pre-clinical data for making reliable compound selection decisions in early lead discovery".
|
